Astrazeneca Plc (AZN)

On September 8, 2026, CNBC reported that AstraZeneca PLC (NYSE:AZN) released full results from two successful late-stage trials of tozorakimab, an experimental drug for chronic obstructive pulmonary disease...

On September 5, 2026, Bloomberg reported that the FDA granted accelerated approval to AstraZeneca PLC (NYSE:AZN)’s camizestrant, sold as Etcamah, for a genetically driven form of metastatic breast cancer...

AstraZeneca PLC (NYSE:AZN)'s breast cancer pill Etcamah (camizestrant) failed to meet the primary endpoint in the Phase III SERENA-4 trial, dealing a setback to one of the company’s key oncology growth...

Toward the end of the lightning round on September 8, when a caller inquired about AstraZeneca PLC (NYSE:AZN), Mad Money host Jim Cramer commented: Alright, now, AstraZeneca reminds me of a company, it...

Amgen Inc.

AstraZeneca plc (NASDAQ:AZN) is exploring whether one of its biggest cancer drugs can work better with a carefully selected partner.

On August 27, AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) scored a shared clinical victory.

Ionis Pharmaceuticals, Inc. ($IONS) shares dropped about 10% in premarket trading after a large cardiovascular trial of pelacarsen, a drug develope...

Shares in pharmaceuticals giant AstraZeneca ($AZN) and peer Amgen ($AMGN) both dropped in pre-market trading despite hailing successful trial resul...